An interventional study of extracorporeal shockwave therapy (ESWT) and Sham Comparator in Knee Osteoarthristis, ACL Injuries and Post-Traumatic, sponsored by Spaulding Rehabilitation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment
This study is recruiting current or former athletes who had ACL reconstruction surgery over a year ago and have been diagnosed with knee osteoarthritis (OA). We are doing the research to investigate the effects of extracorporeal shockwave therapy (ESWT) on pain, function, biomechanics, knee range of motion and strength, inflammation, and joint structure and integrity of the knee.
The goal of this study is to characterize redox homeostasis in post-traumatic osteoarthritis (PTOA), with the goal of examining the impact of extracorporeal shockwave therapy (ESWT). We will explore the following aims:
Specific Aim 1: Investigate the effects of ESWT treatment on participant-reported functional outcomes and quality of life in individuals with PTOA of the knee. We hypothesize that those in ESWT group will report greater improvements in pain level, function and quality of life compared to those individuals in the sham group.
Specific Aim 2: Determine if ESWT influences gait biomechanics of participants with PTOA. We hypothesize that those in ESWT group will display biomechanics during gait that more closely resemble the biomechanics of a healthy individual. We anticipate that this aim will identify if a more favorable inflammation burden will reduce abnormal biomechanics, or if further interventions will be necessary.
Specific Aim 3: Investigate the influence of ESWT on joint conductivity and inflammation of the knee using bioimpedance spectroscopy (BIS). This has yet to be explored in the PTOA population and thus our objective is to explore knee-site tissue changes in PTOA following ESWT. Thermal pattern has been used to identify active inflammation in the osteoarthritic knee with respect to a healthy knee. We hypothesize that there will be improvements in tissue changes and thermal pattern in the knee measured by BIS and thermal camera following ESWT.
Specific Aim 4: Evaluate baseline values of knee range of motion, lower extremity strength, and bone health and determine if ESWT may influence these measures. We will collect measures of knee range of motion, quadriceps isometric strength and rate of torque development with handheld dynamometry, and measurements of bone density with DXA scans. We hypothesize that knee range of motion, quadriceps strength and rate of torque development will yield greater improvements following ESWT compared to sham treatment.
Specific Aim 5: Assess the influence of ESWT on chronic pain. We will investigate if ESWT will reduce chronic pain in participants with knee OA, thus resulting in improved functional outcomes. We hypothesize that individuals will have reduced levels of PPT and improved scores on PainDETECT following ESWT compared to sham treatment.
Specific Aim 6: Evaluate the effects of ESWT on bone turnover and joint integrity. We hypothesize that those in ESWT group will demonstrate more favorable joint integrity compared to individuals in the sham group.
Specific Aim 7: Investigate the effects of ESWT treatment on redox and inflammatory biomarkers. We hypothesize that redox and inflammatory biomarkers will increase above pre-treatment values following ESWT treatment and that ESWT will provoke a greater biomarker response than sham treatment. Finally, upon resolution of this acute response, we hypothesize that biomarker values assessed after treatment completion will reveal favorable redox balance and inflammation burden relative to pre-treatment values and be associated with improvement in functional measures of knee function.
This is a prospective, placebo control randomized control trial with an elective cross-over design that aims to understand influence of ESWT in the management of PTOA after ACL reconstruction. Participants involvement will last 4-8 months depending on participant allocation and whether they elect to participate in cross-over portion of study. Each participant will complete biomechanical assessment of gait using instrumented treadmill while wearing motion capture markers, accelerometers and EMGs, have thermal images and bioimpedance measures collected, have their height and leg length measured, complete measures of knee range of motion and quadriceps strength. To document presence and degree of PTOA, each participant will complete weight-bearing (WB) X-rays of both knees, an MRI of involved knee, and complete bone density scans (DEXA). Blood and serum biomarkers of inflammation and candidate markers of joint injury and healing will be recorded. Each participant will complete functional outcomes before and after treatment. To ensure standard exercise program is completed per standard of care, each participant will be instructed on a home exercise program to complete during the study. During the treatment session, participants will receive either ESWT or sham ESWT with measures of oxidative stress obtained. At baseline, treatment session 3, 8-weeks and 4-months, participants will complete patient reported outcome measures (PROMs). At the 4-month time point after starting ESWT, participants will repeat the following measures: PROMs, biomechanical assessment with surface EMG, thermal images, bioimpedance, knee range of motion, quadriceps strength, quantitative sensory testing (QST), MRI of injured knee, and venous and fingerstick blood draws. For those participants who were randomized to the sham ESWT group, they will have the option to cross-over at 4 months and receive ESWT.
Study Procedures:
Participants will be randomized into ESWT treatment group or sham ESWT control group using a block randomization generator that is implemented into REDCap. Based on anticipated 20% attrition, our goal is to assign 35 participants to each group.
Control Group: Sham ESWT Arm:
All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits. After collecting baseline variables and after blood is drawn, they will receive sham ESWT using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
Treatment Group: ESWT Arm:
All participants will review the exercise program prior to randomization and receiving treatment. Participants in the ESWT group will receive ESWT. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits. After collecting baseline variables and after blood is drawn, they will receive ESWT using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus. Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. Half of treatment (1500 strikes) will be delivered to the patellar tendon and 1500 strikes to the quadricep tendon and distal quadricep muscles with the patient in supine position with knee flexed during treatment to patellar tendon and knee in extension to treat the quadricep region. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars will be administered and this will also be performed to participant tolerance. With the patient in supine position with knee bent, anatomical landmarks of tibial plateau and femoral condyle will be identified. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle. At each location, the patient will receive a lower energy setting of 200 shocks to 0.05 MJ, then 200 at .10 MJ, 200 at 0.12 MJ and, 200 AT 0.15 MJ, and finally 200 at .20 MJ to improve patient comfort to higher energy settings. These energy settings are consistent with mild to moderate ESWT which are commonly used in clinical practice to treat knee OA. During the ESWT treatment, a curtain will obscure participants from viewing their leg to blind them from treatment they are receiving. Standard protocol for the ESWT procedure will be followed, including safety assessment and monitoring. Additionally, the patient will be prescribed a post-ESWT exercise protocol that is part of the standard of care, which will be reviewed prior to first treatment and before treatment allocation.
Visit Details:
Participants will come in for a total of seven to eight in-person visits during the study, which will depend on if baseline visits are completed over two or three sessions based on convenience for participants. For those participants who elect to participate in cross-over at 4 months, they will complete up to 12 visits. Participant reported outcomes will be collected using online survey through REDCap at 8-weeks (8 weeks is based on initial time of ESWT or sham ESWT). The baseline visit will be a pre-trial assessment to obtain baseline values for each patient. During the baseline visits, participants will run on an instrumented treadmill with motion capture markers, accelerometers, and surface EMG. Participants will have knee inflammation information recorded using thermal imaging and tissue electrical characteristics using bioimpedance measures, have their heigh and leg length measured, have their knee range of motion and strength measured, perform quantitative sensory testing (QST), have an assessment of bone health and body composition with a DEXA scan, have standard AP and lateral, as well as WB X-rays taken of their knees, complete surveys regarding pain and function of the affected joint, and have blood drawn to measure blood and serum biomarkers and obtain an MRI of participants' arthritic knee.
After the pre-trial assessment participants will come in for one treatment session. A post- treatment exercise protocol will be reviewed with all participants prior to randomization. During the treatment session participants will be given ESWT or sham ESWT depending on what treatment group they are randomized to. Blood will also be drawn to analyze biomarkers. Participants will attend two additional treatment sessions. Blood draw and finger stick will be performed prior to each treatment session. Participants will complete questionnaires at the third treatment session and will be sent questionnaires electronically through REDCap to be completed at 8 weeks follow-up. Participants will return at 4 months for repeat MRI, thermal imaging, bioimpedance, knee ROM, quadriceps strength and torque measures, QST, biomechanical assessment with surface EMG, and will complete final questionnaires. At 4 months, participants in the sham ESWT treatment group will have the option to elect to cross-over and receive three ESWT treatments.
625 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 192 are open to participants now.
This study's planned enrollment of 70 is above the median of 56 across 458 interventional studies indexed under Anterior Cruciate Ligament Injuries.
Browse Anterior Cruciate Ligament Injuries studies →Spaulding Rehabilitation Hospital is the lead sponsor of 117 studies on the registry; 27 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 days to account for ongoing challenges for respiratory illness and scheduling/traveling conflicts. After collecting baseline variables and after blood is drawn, they will receive sham ESWT administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
Device: Sham Comparator
All participants will review the exercise program prior to randomization and receiving treatment. Participants in the ESWT group will receive ESWT. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Radial and focused shockwave will be delivered to the knee and lower leg landmarks. The energy settings that will be used are consistent with mild to moderate ESWT which are commonly used in clinical practice to treat knee OA. During the ESWT treatment, a curtain will obscure participants from viewing their leg to blind them from treatment they are receiving. Standard protocol for the ESWT procedure will be followed, including safety assessment and monitoring. Additionally, the patient will be prescribed a post-ESWT exercise protocol that is part of the standard of care, which will be reviewed prior to first treatment and before treatment allocation is decided to minimize risk of bias.
Device: extracorporeal shockwave therapy (ESWT)
Participants will receive ESWT administered by research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus.Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle.
All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 day. Sham ESWT will administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
Knee Injury and Osteoarthritis Outcome Score (KOOS)
The KOOS is is a 42-item survey with 5 subscales designed to measure patient health, symptoms, and functionality of the knee. It is scored from 0-100, with higher score correlated with better function.
Time frame: From baseline to 4-month follow up with intermediate measure at 8 weeks
Biomarkers of oxidative stress and inflammation
Biomarkers of oxidative stress and inflammation (for example, interleukins, MMPs, C-reactive protein) and other candidate biomarkers of interest such as Klotho and Eotaxin will be collected.
Time frame: Baseline, at each of the three treatment sessions and at 4 months
Biomechanics
Lower extremity biomechanics will be collected on an instrumented treadmill and overground using motion capture and EMG with participants walking and running at both lab and self-selected speeds.
Time frame: Baseline and 4 months
Knee range of motion
Maximum knee extension and knee flexion range of motion will be measured with a goniometer.
Time frame: Baseline and 4 months
Quadriceps strength and power
All quadriceps testing (in 90° of knee flexion) for both limbs will be performed isometrically using hand-held dynamometry (HHD). For each task, a participant will be positioned with the HHD and taken through a series of sub-maximal contractions to allow for warm-up and acclimation. The warm-up will consist of contractions at 50, 75 and 100% of their self-perceived maximal isometric contraction with one minute of rest between each contraction.
Time frame: Baseline and 4 months
Quantitative Sensory Testing (Pain Pressure Threshold)
Pressure Pain Threshold (PPT) will be measured with an algometer. The algometric measurements will be performed while the participant is in the side-lying position. PPT will subsequently be assessed at the medial aspect of the patient's affected knee (approximately 1-2 cm mediolateral to the medial femoral tubercle) followed by the unaffected knee. PPT will be measured 3 times at 2-min intervals.
Time frame: Baseline and 4 months
Non-contrast MRI
Participants will undergo non-contrast MRI of the involved knee (knee with PTOA).
Time frame: Baseline and 4 months
Thermal Imaging
Thermal imaging will be taken using a FLIR Ex thermal camera. Thermal patterns at the knee will be measured to learn about the inflammatory state of the joint.
Time frame: Baseline and 4 months
Bioimpedance
Bioimpedance at the knee will be measured to learn about the electrical characteristics of the joint. Bioimpedance will be measured at multiple frequencies between 1 kHz and 1 MHz using tetrapolar electrodes on either side of the knee joint. Gel electrodes will then be positioned to the medial and lateral surfaces of the knee joint to measure impedance transversely. A sinusoidal current stimulus with amplitude and frequency compliant with the IEC 60601- 1 safety standard will be used.
Time frame: Baseline and 4 months
Knee X-rays
Standing PA, lateral and patellofemoral radiographs of bilateral knees will be taken at baseline to assess joint space and for detection of presence and severity of osteoarthritis.
Time frame: Baseline
Bone Mineral Density Scan by DEXA
Hip, lumbar spine, and total body DEXA scans will be performed to assess bone health.
Time frame: Baseline
Height in meters
Height of participants will be measured without shoes using a wall-mounted stadiometer.
Time frame: Baseline
Leg length in meters
Leg length will be measured using markers from the motion capture static trial--measuring the length of each leg from the greater trochanter to lateral malleolus
Time frame: Baseline
Weight in kg
Weight will be calculated on the instrumented treadmill during static calibration of biomechanical assessment.
Time frame: Baseline
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
The PROMIS-29 is a questionnaire that addresses the 7 domains of depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities, with 4 questions each, and an additional pain intensity rating. Higher score represents better function.
Time frame: From baseline to 4-month follow up with intermediate measure at 8 weeks
Single Assessment Numeric Evaluation (SANE)
The SANE is a patient rating of their current illness in relation to their pre-injury baseline from 0-100. Higher score is correlated with better function .
Time frame: From baseline to 4-month follow up with intermediate measure at 8 weeks
Patient Acceptable Symptom State (PASS)
PASS is a single question aimed at reflecting the state at which participants consider themselves to be well. A lower score is correlated with better function.
Time frame: From baseline to 4-month follow up with intermediate measure at 8 weeks
Visual Analog Scale (VAS)
VAS is a pain rating on a continuous scale from 0 to 10. Higher score is correlated with worse function.
Time frame: From baseline to 4-month follow up with intermediate measure at 8 weeks
PainDETECT
PainDETECT is a 12-question screening questionnaire that is used to detect neuropathic pain. Higher scores are correlated with worse pain severity.
Time frame: From baseline to 4-month follow up with intermediate measure at 8 weeks
Lateral Preference Inventory (LPI)
The LPI is a brief, 16-item questionnaire, which validly measures hand, foot, eye, and ear preference. It is a categorical variable that assigns a number to a side (left, right or both)
Time frame: Baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Deidentified data will be shared once the study results are published in peer reviewed journal
Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.
Of 277 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's planned 29 months is close to that.
Counting every sponsor, half of 286 studies reached it within 30 months; a quarter within 14 and three quarters within 70.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jul 2026 → Sep 2027 and completion Sep 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anterior Cruciate Ligament Injuries →
Spaulding Rehabilitation Hospital →